Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy.

International journal of medical sciences - 1 Jan 2017

Nakamoto Shingo, Imazeki Fumio, Kanda Tatsuo, Wu Shuang, Nakamura Masato, Yasui Shin, Tawada Akinobu, Mikata Rintaro, Chiba Tetsuhiro, Arai Makoto, Yokosuka Osamu, Shirasawa Hiroshi

Abstract excerpt

BACKGROUND: Genetic variation near the interferon lambda 3 (IFNL3) is known to be associated with response to pegylated interferon (pegIFN) and ribavirin combination therapy in patients with chronic hepatitis C virus (HCV) infection which is often accompanied by hepatic steatosis. AIMS: We examined whether this genetic variation is associated with host lipids and treatment response. METHODS: A total of 101...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fatty Liver

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Interferons

Share to Interleukins

Share to Ribavirin

Source

Open in PubMed Open full text

Identifiers

PMID: 29104462
DOI: 10.7150/ijms.20171
PMCID: PMC5666539

Genes

IFNL3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy.PMID 29104462Read ↗

PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C.Semantic proximity Read ↗

A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection.Semantic proximity Read ↗

Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection.Semantic proximity Read ↗

Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3.Semantic proximity Read ↗

Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.Semantic proximity Read ↗

Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis.Semantic proximity Read ↗

The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection.Semantic proximity Read ↗

Interferon lambda polymorphisms associate with body iron indices and hepatic expression of interferon-responsive long non-coding RNA in chronic hepatitis C.Semantic proximity Read ↗

Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C.Semantic proximity Read ↗

Can IFNL3 polymorphisms predict response to interferon/ribavirin treatment in hepatitis C patients with genotype 3?Semantic proximity Read ↗

Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors?Semantic proximity Read ↗

Impact of comorbid hepatic steatosis on treatment of chronic hepatitis C in Japanese patients and the relationship with genetic polymorphism of IL28B, PNPLA3 and LDL receptor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.